ClinicalTrials.gg
RecruitingNCT06959082Updated Sep 2, 2026

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

A Phase 2 interventional study of VS-101 and Cisplatin in Head and Neck Cancer Squamous Cell Carcinoma, sponsored by VSPharmTech Co.,Ltd.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by VSPharmTech Co.,Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Neoplasms, Squamous Cell with a site in United States — 8 open to participants now, 11 under way, none of them phase 3. Neoplasms, Squamous Cell · United States.

Planned enrollment
30th of 53
30 · median 36
Started
2025
with 3 others
Phase 2
18 of 58
2 open now
Primary completion
2027-12
later than 5 of 10 live
Registered
55th of 58
by date

Among the 58 studies in Neoplasms, Squamous Cell with a site in United States, this one is the 30th largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 55th registered.

Neoplasms, Squamous Cell

111 studies on the registry are indexed under Neoplasms, Squamous Cell; 19 are open to participants now.

Browse Neoplasms, Squamous Cell studies →

Open to participants now

8 of the 58 studies in Neoplasms, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Neoplasms, Squamous Cell studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Neoplasms, Squamous Cell with a site in United States, or all of them as a file.
02

Study summary

This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.

03

Conditions studied

  • Head and Neck Cancer Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged more than 18 years at the time of ICF signing
  2. Diagnosed based on position emission tomography (PET), computed tomography (CT), or magnetic resonance imaging (MRI) with confirmed (histologic or cytological) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
  3. Defined by American Joint Committee on Cancer [AJCC] Guidelines 8th Edition:

    • Oral cavity, hypopharynx, or larynx (independent of p16): Stage III, IVa, IVb per TNM guidelines; or
    • Oropharyngeal p16 negative disease: Stage III, IVa, IVb per TNM guidelines; or
    • Oropharyngeal p16 positive disease: Stage III per TNM guidelines
  4. Have based on 1.1
  5. Participants with head and neck cancer who have limited to those receiving definitive CRT without surgical excision
  6. Participants prescribed standard intensity-modulated radiation therapy (IMRT) with a cumulative planned dose of approximately 70 Gy
  7. Participants with (ECOG) Performance Statue (PS) of 0 \~ 2
  8. Participants with the status of National Cancer Institute- (NCI CTCAE) version 6.0 Grade 2 if stable and not , or lower for acute or chronic adverse reaction at the time of screening
  9. Participants with an expected survival period of at least 20 weeks
  10. Participants who can comply with the requirements of the clinical trial protocol
  11. Ability to understand and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  1. Medical History

    1. Patients with a history of prior radiation to the head and neck region which overlap with the planned radiation fields (or cumulative doses exceed the constraints for organs-at-risk [OAR]) or with a known susceptibility to radiation.
    2. Patients with active or uncontrolled or medical or psychiatric disorders that, in the investigator's opinion, may interfere with , adherence, or patient safety. Stable medical or psychiatric conditions under a stable dose regimen are permitted.
    3. Patients with a history of uncontrolled seizure disorder. Patients with a remote history of a single provoked seizure or well-controlled seizures on stable monotherapy may be eligible.
    4. Patients who are unable to swallow the study tablet at the screening visit, unless a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube is already in place for clinically indicated reasons and the patient is clinically stable.
  2. Patients who show abnormalities in the following test results at the time of screening:

    1. (ALT) or aspartate aminotransferase (AST) >2.5 × (ULN)
    2. Creatine clearance ≤50 mL/min (using (C-G) formula)
    3. (ANC) \<1,500/µL
    4. \<100,000/µL
    5. \<9 g/dL
    6. Serum calcium >1.5 × ULN
    7. Total > 2 × ULN
    8. (PT) (International Normalized Ratio [INR]) >1.5 × ULN or activated partial thromboplastin time (aPTT) (sec)
    9. Positive result for serum tests ( or C virus, [HIV], rapid plasma reagin [RPR] test)
    10. Patients who show significant abnormalities in (ECG) test results (e.g., > 450 msec)
  3. Patients who received hypofractionated chemoradiation regimens (> 2 Gy per day) Note:If it is established that the abnormal lab values are a consequence of their underlying malignant disease rather than any other co-existing condition, reflect minor variations attributable to individual differences or testing conditions, and is not considered clinically significant, the Principal Investigator (PI) may discuss the case with the Medical Monitor to determine eligibility.
  4. Patients with known to components or of clinical drugs
  5. Participants with a history of drug addiction within 3 months before ICF signing, unless a Urine drug screen negative result is obtained prior to randomization
  6. Drugs and Treatments:

    1. Participants who have administered strong cytochrome P450 (CYP) 3A4 or CYP2D6 inducers or inhibitors within 14 days of baseline or 5 times the drug's half-life, whichever is longer.
    2. Participants who received chemotherapy within 14 days of baseline (drugs or treatment known to have anticancer effects such as cytotoxic chemotherapy, antihormonal therapy, and targeted therapy).
    3. Participants who required intravenous antibiotics, antivirals, or antifungals for active or uncontrolled infection at baseline.
    4. Participants who have administered benzodiazepines (e.g., lorazepam) that causes clinically significant sedation (stable low dose is permitted).
    5. Participants who participated in another clinical trial within 4 weeks of the baseline and administered the clinical trial drug
  7. Participants and their spouses (or partners) with who are not using medically acceptable methods of for the duration of the trial and for 14 months (in female participants) and 11 months (in male participants) after the last dose of cisplatin treatment
  8. Participants who, in the judgment of other investigators, are not suitable to participate in the study"
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    2 mg of VS-101 + CRT

    2 mg of VS-101 + CRT

    Drug: VS-101 · Drug: Cisplatin · Radiation: Radiation

  • Experimental
    5 mg of VS-101 + CRT

    5 mg of VS-101 + CRT

    Drug: VS-101 · Drug: Cisplatin · Radiation: Radiation

  • Placebo comparator
    Only CRT

    Only CRT

    Drug: Cisplatin · Radiation: Radiation

Interventions

  • DrugVS-101

    VS-101

  • Cisplatin

  • RadiationRadiation

    Radiation

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The proportion of participants who achieve an ORR at 6 months and 12 months will be summarized with the 95% confidence interval on the mITT and PP samples.

    Time frame: 6 months and 12 months

Secondary outcomes

  1. Disease control rate (DCR)

    proportion of subjects who have a complete response (CR), partial response (PR), or stable disease (SD) at 6 months and 12 months will be summarized with the 95% confidence interval on the mITT and PP samples.

    Time frame: 6 months and 12 months

  2. Best overall response (BOR)

    The BOR will be based on all post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy. BOR will be summarized for the following categories: CR, PR, SD, PD and non-evaluable.

    Time frame: 6 months and 12 months

  3. Progression-free survival (PFS)

    The PFS will be analyzed using Kaplan-Meier methods on the mITT and PP samples. KM estimates and associated two-sided 95% confidence intervals will be presented for each cohort. Participants who have no documented progression and are still alive at the time of analysis will be censored at the time of the latest date of assessment.

    Time frame: At 6 month and 1 year

  4. Locoregional control (LRC)

    Rate of Locoregional recurrence after end of treatment (FDG-PET/CT scan).

    Time frame: At 6 month and 1 year

  5. Distant metastasis (DM)

    The proportion of participants who develop DM will be summarized with the 95% confidence interval on the mITT and PP samples

    Time frame: through study completion, at most 1 year

  6. Overall survival (OS)

    The OS will be analyzed using Kaplan-Meier methods on the mITT and PP samples. KM estimates and associated two-sided 95% confidence intervals will be presented for each cohort, and 1-year survival estimate will be calculated

    Time frame: 1 year

  7. Changes in tumor size

    Tumor imaging (CT and MRI) will be performed.

    Time frame: through study completion, at most 1 year

  8. Number and severity of treatment-emergent adverse events (TEAEs), treatment-related AEs, and serious adverse events (SAEs) for all dose groups according to the NCICTCAE version 5.0

    AE will be measured by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: through study completion, at most of 1 year

  9. Health-related quality of life (HR-QoL)

    FACT-H\&N V4. * Physical Well-Being * Social/Familiy Well-Being * Emotional Well-Being * Functinal Well-Being

    Time frame: at week1, week8, week11, week 19, week 27 and week 52

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 6, 2025
StartActual
Jun 11, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06959082
Lead sponsor
VSPharmTech Co.,Ltd.
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Jun 11, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion